Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation

Abstract

Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate exposure and response.

Methods This retrospective cohort study used administrative health data for NVAF patients dispensed dabigatran etexilate between July 1, 2011 and December 31, 2015. Outcomes of cerebrovascular accident (CVA), systemic embolism, and hemorrhage were extracted. Simulated pharmacokinetic parameters were obtained using a published population pharmacokinetic model of dabigatran etexilate. Area under the curve calculated for a 24-hour period at steady state (AUC_ss), the exposure parameter, was derived using these simulations and the dosing data and the exposure–response relationship were investigated. The risk of adverse outcomes at AUC_ss quartiles was compared using Poisson regression and expressed using incidence rate ratios (95% confidence interval) adjusted for known potential confounders.

Results In total, 2,660 NVAF patients had been dispensed dabigatran etexilate. For these patients there was a decreased risk of hemorrhage (0.51, 0.32–0.79) when dabigatran AUC_ss was in the second quartile range of 1.70 to 1.96 mg h/L and thromboembolism/CVA (0.34, 0.16–0.76) when in the third quartile range of 1.97 to 2.26 mg h/L. An increased risk of hemorrhage (1.68, 1.18–2.38) was observed when AUC_ss was in the fourth quartile range of 2.27 to 12.76 mg h/L.

Conclusion An exposure–response relationship for dabigatran etexilate was described, where the most effective response was observed when AUC_ss was in the range of 1.70 to 2.26 mg h/L. Hence, it is feasible to develop guidance for optimal dosing to improve outcomes for patients with NVAF.

Keywords

dabigatran etexilate - therapeutic drug monitoring - hemorrhage - stroke - population pharmacokinetic

• References

• 1 Simpson B, Reith D, Medlicott N. , et al. Utilisation of New Zealand primary care electronic data to guide clinical decision support system design—a retrospective cohort for dabigatran. Clin Ther 2017; 39: e7
• 2 Bell S, Nand J, Spriggs D, Young L, Dawes M. Initial experience with dabigatran etexilate at Auckland City Hospital. N Z Med J 2012; 125 (1349): 105-107
• 3 Thorne K, Jayathissa S, Dee S. , et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J 2014; 44 (03) 261-265
• 4 Boehringer Ingelheim (N.Z.) Limited. Pradaxa: New Zealand Datasheet. Available at: http://www.medsafe.govt.nz/other/copyright.asp . Accessed November 2017
• 5 Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016; 172 (03) 315-336
• 6 Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014; 349: g4670
• 7 Comuth WJ, Henriksen LØ, van de Kerkhof D. , et al. Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration. Thromb Res 2018; 164: 32-39
• 8 Boehringer Ingelheim International GmbH. Pradaxa 110 mg hard capsules. Available at: https://www.medicines.org.uk/emc/product/6229/smpc#companyDetails . Accessed September 5, 2018
• 9 Douxfils J, Ageno W, Samama CM. , et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
• 10 Chin PKL, Wright DFB, Patterson DM, Doogue MP, Begg EJ. A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. Br J Clin Pharmacol 2014; 78 (03) 599-609
• 11 Amiral J, Dunois C, Amiral C, Seghatchian J. An update on laboratory measurements of Dabigatran: smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma. Transfus Apheresis Sci 2016; 54 (03) 428-437
• 12 Committee for Medicinal Products for Human Use (CHMP). Assessment report. Pradaxa. International non-proprietary name: dabigatran etexilate. 2014 . Available at: https://www.ema.europa.eu/en/documents/variation-report/pradaxa-h-c-829-ii-0048-g-epar-assessment-report-variation_en.pdf . Accessed June 27, 2019
• 13 Rottenstreich A, Zacks N, Kleinstern G. , et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 2018; 45 (04) 543-549
• 14 Poli S, Härtig F, Spencer C. , et al. Diagnostic accuracy of a novel chromogenic direct thrombin inhibitor assay: clinical experiences for dabigatran monitoring. Thromb Haemost 2017; 117 (12) 2369-2375
• 15 Best Practice. Decision Support for Health Professionals. Available at: http://www.bestpractice.net.nz/ . Accessed December 3, 2018
• 16 New Zealand Ministry of Health. Pharmaceutical Collection. 2016 . Available at: https://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/collections/pharmaceutical-collection . Accessed June 27, 2019
• 17 Liesenfeld KH, Lehr T, Dansirikul C. , et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9 (11) 2168-2175
• 18 U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry. E7 Studies in Support of Special Populations: Geriatrics. Questions and Answers. 2012
• 19 Committee for Human Medicinal Products (CHMP). Adequacy of Guidance on the Elderly Regarding Medicinal Products for Human Use. European Medicines Agency. 2007
• 20 New Zealand Ministry of Health. National Minimum Dataset (Hospital Events) data dictionary. 2015
• 21 National Centre for Classification in Health (Australia). The International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian modification (ICD-10-AM). 6th ed. Lidcombe, NSW: National Centre for Classification in Health; 2008
• 22 Coleman JS. Introduction to Mathematical Sociology. New York, NY: Free Press; 1964
• 23 Simpson BH, Reith D, Medlicott NJ, Smith A. Deprivation and inequalities lead to worse outcomes with dabigatran etexilate. J Prim Health Care 2018; 10 (04) 303-311
• 24 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
• 25 Reilly PA, Lehr T, Haertter S. , et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
• 26 Arnason T, Wells PS, van Walraven C, Forster AJ. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006; 118 (02) 253-262
• 27 Woodfield R, Grant I, Sudlow CL. ; UK Biobank Stroke Outcomes Group; UK Biobank Follow-Up and Outcomes Working Group. Accuracy of electronic health record data for identifying stroke cases in large-scale epidemiological studies: A systematic review from the UK biobank stroke outcomes group. PLoS One 2015; 10 (10) e0140533